Tazarotene is in the retinoid family (think Retin-A® and its many cousins) and has been shown to have advantages in reversing sun damage, improving lines and wrinkles, as well as treating psoriasis. It is also highly effective for controlling acne. You may have already heard of this multi-tasking wonder drug under the brand names of – Avage® 1.0% Cream and Tazorac® which comes in 0.5% and 1.0% cream and gel formulations (Allergan).
Well the big news about Tazarotene is that Stiefel, a GSK company, submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), for Tazarotene foam for the topical treatment of facial acne vulgaris in patients 12 years of age or older. Tazarotene foam will be subject to evaluation and approval by the regulatory authorities before it can be made available to physicians for prescribing to patients.
According to Jim Lee, Vice President of Clinical/Medical Dermatology at Stiefel, a GSK Company, “We believe that the Tazarotene active in a foam instead of a cream or gel will be helpful for people with mild to moderate facial acne.” Among the potential advantages of a foam is a little thing called spreadability. Foams can be easier to use for larger surface areas – like the chest or backne and also for the full face. When dealing with acne, which is chronic, using your medication all over the affected area is key to keeping it under control.
We can look forward to seeing the new Tazarotene foam on the market hopefully some time in the second half of 2012, depending upon the FDA.